Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 1.736
5-Year Impact Factor – 2.135
Index Copernicus  – 168.52
MEiN – 70 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

Ahead of print

doi: 10.17219/acem/161461

Publication type: research letter

Language: English

License: Creative Commons Attribution 3.0 Unported (CC BY 3.0)

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

Cite as:

Stępień M, Świątoniowska-Lonc N, Knysz B, et al. An epidemiological and retrospective study in a cohort qualified for SARS-CoV-2 vaccination in the region of Lower Silesia, Poland [published online as ahead of print on March 15, 2023]. Adv Clin Exp Med. 2023. doi:10.17219/acem/161461

An epidemiological and retrospective study in a cohort qualified for SARS-CoV-2 vaccination in the region of Lower Silesia, Poland

Monika Stępień1,A,B,C,D,E,F, Natalia Świątoniowska-Lonc2,A,B,C,D,E,F, Brygida Knysz1,A,B,C,D,E,F, Beata Jankowska-Polańska2,A,B,C,D,E,F, Amadeusz Kuźniarski3,A,D,E,F, Agnieszka Piwowar4,A,D,E,F, Małgorzata Zalewska1,A,B,C,D,E,F

1 Department of Infectious Diseases, Liver Diseases and Acquired Immune Deficiencies, Wroclaw Medical University, Poland

2 Center for Research and Innovation, 4th Military Teaching Hospital, Wrocław, Poland

3 Department of Prosthetic Dentistry, Wroclaw Medical University, Poland

4 Department of Toxicology, Wroclaw Medical University, Poland


Background. Since the beginning of the coronavirus disease (COVID-19) pandemic, numerous infections have been observed with various symptoms and degrees of severity. Not all patients have had a confirmation of infection made using reverse transcription polymerase chain reaction (RT-PCR) or antigen tests. It has been observed that some people, including convalescents or those without knowledge of a past infection, perform serological tests to detect anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies.
Objectives. We aimed to evaluate the levels of anti-SARS-CoV-2 immunoglobulin G (IgG) antibodies in a cohort of convalescents and in individuals not previously infected, who were willing to get vaccinated. We also aimed to assess several socio-clinical factors associated with participants’ humoral responses.
Material and Methods. We recruited 298 individuals from the region of Lower Silesia who were willing to get vaccinated for SARS-CoV-2. The participants were divided into 2 groups: convalescents (group I) and participants without a past infection (group II). Several seropositive individuals in group II were identified, and they were transferred to group I, resulting in a final distribution of 171 individuals in group I and 127 individuals in group II. For serological testing, the QuantiVac anti-SARS-CoV-2 (IgG) enzyme-linked immunosorbent assay (ELISA) was used.
Results. The results showed the presence of anti-SARS-CoV-2 IgG antibodies in participants from group I, with an average number of 190.3 IU/mL. Twenty-three participants (13.45%) did not have a detectable level of antibodies despite a previous SARS-CoV-2 infection. In 21 participants (12.28%), antibodies were detected despite no previous symptoms of infection (average level: 145.0 IU/mL).
Conclusion. Older participants were more likely to experience a symptomatic SARS-CoV-2 infection, and the severity of the symptoms was related to higher antibody titers seen later after COVID-19. Numerous individuals from group II were unaware of past SARS-CoV-2 infections. In several participants, antibodies were not detected despite a previous infection.

Key words

antibodies, serology, seronegative, SARS-CoV-2, asymptomatic

Graphical abstract

Graphical abstracts

References (13)

  1. Our World in Data. Coronavirus (COVID-19) vaccinations. 2023. Accessed December 17, 2022.
  2. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet. 2020;395(10229):1054–1062. doi:10.1016/S0140-6736(20)30566-3
  3. Milani GP, Dioni L, Favero C, et al. Serological follow-up of SARS-CoV-2 asymptomatic subjects. Sci Rep. 2020;10(1):20048. doi:10.1038/s41598-020-77125-8
  4. Rijkers G, Murk JL, Wintermans B, et al. Differences in antibody kinetics and functionality between severe and mild severe acute respiratory syndrome coronavirus 2 infections. J Infect Dis. 2020;222(8):1265–1269. doi:10.1093/infdis/jiaa463
  5. Liu G, Rusling JF. COVID-19 antibody tests and their limitations. ACS Sens. 2021;6(3):593–612. doi:10.1021/acssensors.0c02621
  6. Barek MdA, Aziz MdA, Islam MS. Impact of age, sex, comorbidities and clinical symptoms on the severity of COVID-19 cases: A meta-analysis with 55 studies and 10014 cases. Heliyon. 2020;6(12):e05684. doi:10.1016/j.heliyon.2020.e05684
  7. Johansson MA, Quandelacy TM, Kada S, et al. SARS-CoV-2 transmission from people without COVID-19 symptoms. JAMA Netw Open. 2021;4(1):e2035057. doi:10.1001/jamanetworkopen.2020.35057
  8. Bi Q, Lessler J, Eckerle I, et al. Insights into household transmission of SARS-CoV-2 from a population-based serological survey. Nat Commun. 2021;12(1):3643. doi:10.1038/s41467-021-23733-5
  9. Hart WS, Maini PK, Thompson RN. High infectiousness immediately before COVID-19 symptom onset highlights the importance of continued contact tracing. eLife. 2021;10:e65534. doi:10.7554/eLife.65534
  10. Wajnberg A, Amanat F, Firpo A, et al. Robust neutralizing antibodies to SARS-CoV-2 infection persist for months. Science. 2020;370(6521):1227–1230. doi:10.1126/science.abd7728
  11. Horton DB, Barrett ES, Roy J, et al. Determinants and dynamics of SARS-CoV-2 infection in a diverse population: 6-month evaluation of a prospective cohort study. J Infect Dis. 2021;224(8):1345–1356. doi:10.1093/infdis/jiab411
  12. den Hartog G, Vos ERA, van den Hoogen LL, et al. Persistence of antibodies to severe acute respiratory syndrome coronavirus 2 in relation to symptoms in a nationwide prospective study. Clin Infect Dis. 2021;73(12):2155–2162. doi:10.1093/cid/ciab172
  13. Liu W, Russell RM, Bibollet-Ruche F, et al. Predictors of nonseroconversion after SARS-CoV-2 infection. Emerg Infect Dis. 2021;27(9):2454–2458. doi:10.3201/eid2709.211042